BPC-157 vs Cagrilintide (± CagriSema)
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| BPC-157 | Cagrilintide (± CagriSema) | |
|---|---|---|
| Human evidence | ★★★☆☆ | ★★★★☆ |
| Legal status | Not Approved | Not Approved |
| How it works | A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also… | Long-acting amylin receptor (CALCR/RAMP) agonist; amylin slows gastric emptying and enhances satiety through a pathway complementary to GLP-1. CagriSema (cagrilintide + semaglutide) targets ~25% weight loss. |
| In plain English | It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human… | A second gut-fullness hormone (amylin) stacked on top of GLP-1 — two different "I'm full" systems for bigger appetite suppression. |
| Bottom line | The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. | The likely next combo blockbuster; investigational. |
| Availability | Not widely approved | Not widely approved |
Which is better for gut health?
Cagrilintide (± CagriSema) has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
Full breakdowns: BPC-157 · Cagrilintide (± CagriSema).
Common questions
Is BPC-157 or Cagrilintide (± CagriSema) better for gut health?
Cagrilintide (± CagriSema) has the stronger human-evidence rating (★★★★☆ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between BPC-157 and Cagrilintide (± CagriSema)?
BPC-157: The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. — Cagrilintide (± CagriSema): The likely next combo blockbuster; investigational.